Menu
GWAS Study

Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease.

Phillips JM, Dumitrescu LC, Archer DB et al.

40111762 PubMed ID
GWAS Study Type
20513 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

PJ
Phillips JM
DL
Dumitrescu LC
AD
Archer DB
RA
Regelson AN
MS
Mukherjee S
LM
Lee ML
CS
Choi SE
SP
Scollard P
TE
Trittschuh EH
KW
Kukull WA
BS
Biber S
MJ
Mez J
ME
Mahoney ER
CM
Clifton M
LJ
Libby JB
WS
Walters S
BW
Bush WS
EC
Engelman CD
LQ
Lu Q
FD
Fardo DW
WK
Widaman KF
BR
Buckley RF
ME
Mormino EC
SR
Sanders RE
CL
Clark LR
GK
Gifford KA
VB
Vardarajan B
CM
Cuccaro ML
PM
Pericak-Vance MA
FL
Farrer LA
WL
Wang LS
SG
Schellenberg GD
HJ
Haines JL
JA
Jefferson AL
JS
Johnson SC
AM
Albert MS
KC
Keene CD
SA
Saykin AJ
RS
Risacher SL
LE
Larson EB
SR
Sperling RA
MR
Mayeux R
GA
Goate AM
RA
Renton AE
ME
Marcora E
FB
Fulton-Howard B
PT
Patel T
BD
Bennett DA
SJ
Schneider JA
BL
Barnes LL
CC
Cruchaga C
HJ
Hassenstab J
BM
Belloy ME
AS
Andrews SJ
RS
Resnick SM
BM
Bilgel M
AY
An Y
BL
Beason-Held LL
WK
Walker KA
DM
Duggan MR
KB
Klinedinst BS
CP
Crane PK
HT
Hohman TJ
Chapter II

Abstract

Summary of the research findings

Up to 30% of older adults meet pathological criteria for a diagnosis of Alzheimer's disease at autopsy yet never show signs of cognitive impairment. Recent work has highlighted genetic drivers of this resilience, or better-than-expected cognitive performance given a level of neuropathology, that allow the aged brain to protect itself from the downstream consequences of amyloid and tau deposition. However, models of resilience have been constrained by reliance on measures of neuropathology, substantially limiting the number of participants available for analysis. We sought to determine whether new approaches using APOE allele status, age and other demographic variables as a proxy for neuropathology could still effectively quantify resilience and uncover novel genetic drivers associated with better-than-expected cognitive performance while vastly expanding sample size and statistical power. Leveraging 20 513 participants from eight well-characterized cohort studies of ageing, we determined the effects of genetic variants on resilience metrics using mixed-effects regressions. The outcome of interest was residual cognitive resilience, quantified from residuals in three cognitive domains (memory, executive function and language) and built within two frameworks: 'silver' models, which obviate the requirement for neuropathological data (n = 17 241), and 'gold' models, which include post-mortem neuropathological assessments (n = 3272). We then performed cross-ancestry genome-wide association studies (European ancestry, n = 18 269; African ancestry, n = 2244), gene- and pathway-based tests and genetic correlation analyses. All analyses were conducted across all participants and repeated when restricted to those with unimpaired cognition at baseline. Despite different modelling approaches, the silver and gold phenotypes were highly correlated (R = 0.77-0.88) and displayed comparable performance in quantifying better- or worse-than-expected cognition, enabling silver-gold meta-analyses. Genetic correlation analyses highlighted associations of resilience with multiple neuropsychiatric and cardiovascular traits [false discovery rate-corrected P (PFDR) values < 5.0 × 10-2]. In pathway-level tests, we observed three significant associations with resilience: metabolism of amino acids and derivatives (PFDR = 4.1 × 10-2), negative regulation of transforming growth factor beta (TGF-β) production (PFDR = 1.9 × 10-2) and severe acute respiratory syndrome (PFDR = 3.9 × 10-4). Finally, in single-variant analyses, we identified a locus on chromosome 17 approaching genome-wide significance among cognitively unimpaired participants (index single nucleotide polymorphism: rs757022, minor allele frequency = 0.18, β=0.08, P = 1.1 × 10-7). The top variant at this locus (rs757022) was significantly associated with expression of numerous ATP-binding cassette genes in brain. Overall, through validating a novel modelling approach, we demonstrate the utility of silver models of resilience to increase statistical power and participant diversity.

18,269 European ancestry individuals, 2,244 African ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

20513
Total Participants
GWAS
Study Type
No
Replicated
European, African unspecified
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.